Level C· Early human research exploring benefitsProspective StudyPubMed

Comparative Study of Adipose-Derived Stem Cells from Localized Scleroderma Patients and Healthy Donors in Treating Skin Fibrosis.

Li Z., Xiao Y., Kang L., Li Y., Wang HC., Li Z.

Prospective Study on Immune Modulation, Autoimmune Research, published in Plast Reconstr Surg (2024) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Plast Reconstr Surg (2024)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
39348305
DOI
10.1097/PRS.0000000000011779
Citations
3

Abstract (original English)

Background Localized scleroderma (LoS) is an autoimmune disease characterized by fibrosis of the skin and atrophy of the subcutaneous fat tissue. Use of adipose-derived mesenchymal stem cells (ASCs) is a promising treatment approach for LoS. However, ASCs from scleroderma patients (LoS ASCs) have been shown to exhibit altered characteristics compared with ASCs from healthy donors (healthy ASCs). This study aimed to compare the abilities of LoS ASCs and healthy ASCs in treating skin fibrosis. Methods The paracrine ability of ASCs was tested with cytokine array. Bleomycin-challenged mouse models received subcutaneous injection of LoS ASCs and healthy ASCs. Pathologic staining and Western blotting of collagenase type I and α-smooth muscle actin was performed. Fibroblasts derived from LoS lesions (LoS FB) were co-cultured with ASCs, and subjected to RNA sequencing to further explore the similarities and differences in the treatment mechanism. Results In vivo comparison revealed that healthy ASCs had a stronger proliferation ability and secreted higher levels of growth factors and cytokines, including vascular endothelial growth factor A, platelet-derived growth factor fibroblasts, and interleukin-10. Pathologic staining of the skin in mouse models treated with ASCs demonstrated that healthy ASCs were more effective in reducing dermal thickness and collagen deposition, and increasin

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansAnimalsScleroderma, LocalizedMiceSkinFibrosisMesenchymal Stem Cell TransplantationDisease Models, AnimalFemaleMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research